<span item_type="fundamental" item_id="0daf739771b6ac63736f057f10b4b7a7" counter_id="ST/US/MCAGR" env="prod"></span><span item_type="announcement" item_id="519011428648686081" env="prod"></span><p>EPS: As of FY2025 Q1, the actual value is USD -0.06.</p><p></p><h3>Segment Revenue</h3><ul><li>The company has not commenced any operations and does not expect to generate operating revenues until after the completion of its initial Business Combination.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1859035/000182912625003897/mountaincrest5_10q.htm"></span></li></ul><h3>Operational Metrics</h3><ul><li><strong>Net Loss</strong>: For the three months ended March 31, 2025, the company reported a net loss of $181,378, compared to a net loss of $25,537 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1859035/000182912625003897/mountaincrest5_10q.htm"></span></li><li><strong>General and Administrative Expenses</strong>: Increased to $191,225 for the three months ended March 31, 2025, from $83,769 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1859035/000182912625003897/mountaincrest5_10q.htm"></span></li><li><strong>Interest Income</strong>: Interest earned on investments held in the Trust Account was $12,119 for the three months ended March 31, 2025, compared to $73,585 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1859035/000182912625003897/mountaincrest5_10q.htm"></span></li></ul><h3>Cash Flow</h3><ul><li><strong>Net Cash Used in Operating Activities</strong>: For the three months ended March 31, 2025, net cash used in operating activities was - $88,715, compared to - $130,344 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1859035/000182912625003897/mountaincrest5_10q.htm"></span></li></ul><h3>Unique Metrics</h3><ul><li><strong>Common Stock Subject to Possible Redemption</strong>: As of March 31, 2025, 101,104 shares of common stock were subject to possible redemption, presented at redemption value of $11.54 per share.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1859035/000182912625003897/mountaincrest5_10q.htm"></span></li></ul><h3>Future Outlook and Strategy</h3><ul><li><strong>Core Business Focus</strong>: The company intends to complete its proposed Business Combination before the mandatory liquidation date of November 16, 2025, although there is substantial doubt about its ability to continue as a going concern if the Business Combination is not consummated by this date.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1859035/000182912625003897/mountaincrest5_10q.htm"></span></li><li><strong>Non-Core Business</strong>: The company has entered into a Business Combination Agreement with CUBEBIO Co., Ltd., with the closing expected no later than May 15, 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1859035/000182912625003897/mountaincrest5_10q.htm"></span></li></ul>

MOUNTAIN CREST ACQUISITION CORP V | 10-Q: FY2025 Q1 EPS: USD -0.06